Novo Nordisk
United States
1217 articles about Novo Nordisk
-
The new bills result from a three-year investigation that honed in on anti-competitive efforts that have prevented generic drugs and biosimilars from entering the market.
-
Novo Nordisk receives FDA approval of higher-dose Ozempic® 2 mg providing increased glycemic control for adults with type 2 diabetes
3/28/2022
Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved a 2 mg dose of Ozempic® (semaglutide) injection, a once-weekly glucagon-like peptide-1 (GLP-1) analog indicated along with diet and exercise to improve blood sugar in adults with type 2 diabetes and to reduce the risk of major cardiovascular events such as heart attack, stroke or death in adults with type 2 diabetes and known heart disease.
-
First Moscow State Medical University has paused recruiting new patients for its ongoing clinical trials following a disruption in the university’s ability to receive clinical trial samples.
-
Evotec entered into a drug discovery collaboration for metabolic diseases with Eli Lilly, focusing on kidney disease and diabetes.
-
The Danish pharma giant is partnering with EraCal Therapeutics, to develop new obesity-related drug targets.
-
Cardiometabolic disease is an overlooked therapeutic space that represents a huge and growing need as the global population ages, according to panelists speaking at Biotech Showcase.
-
As 2022 gets underway, multiple companies have already announced partnerships that will advance the potential for new medications in various disease indications.
-
On December 28, the U.S. Food and Drug Administration reported there had been 50 novel drug approvals for the year, and that was just for new chemical entities.
-
Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition
12/28/2021
Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed.
-
Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna
12/25/2021
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m., Eastern Time, on December 24, 2021.
-
Biopharma companies are eying the establishment of new facilities across the globe that will bolster their manufacturing strategies. BioSpace rounds up some of the latest announcements.
-
Novo Nordisk to Acquire Dicerna
11/18/2021
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that it has entered into a definitive agreement with Novo Nordisk under which Novo Nordisk will acquire Dicerna.
-
Novo Nordisk and Dicerna are no strangers. The companies have been collaborating on the development of RNAi therapies for liver disease for the past three years.
-
Two weeks after Novartis announced it would sell its nearly one-third voting stake in next-door neighbor Roche, investors are chomping at the bit to find out how that almost $21 billion will be put to work.
-
Research into Alzheimer’s disease is shifting from amyloid plaque and tau protein to neuroinflammation, white matter changes and insulin resistance.
-
Cell and gene therapies are at an inflection point, as increasing quantities of clinical data highlight both their potential and their challenges.
-
BIOCORP and NOVO NORDISK Sign Global Partnership Within Diabetes on Digital Health
9/27/2021
BIOCORP, a French company specialized in the design, development, and manufacturing of innovative medical devices, announces an agreement with Novo Nordisk, a world leader in diabetes care, for the development and distribution of a Mallya smart add-on device for the Novo Nordisk FlexTouch pen used by people with diabetes.
-
The analysis showed a 52-week glucose remission rate of 65.2% among the 69 patients being followed.
-
The massive genetic data mining project aims to gain deeper insight into how human genetic variants affect risk for common complex diseases.
-
Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena’s ATTR Amyloidosis Programme
7/12/2021
Prothena Corporation plc and Novo Nordisk A/S announced that the companies have entered into a definitive purchase agreement under which Novo Nordisk has acquired Prothena’s clinical stage antibody PRX004 and broader ATTR amyloidosis programme.